Mesenchymal stem cells are expected to reverse the current status of Parkinson's treatment

[Farooqji]

In 2019, Hebei Medical University reported that they performed peripheral intravenous drip transplantation of human umbilical cord mesenchymal stem cells on 34 patients with Parkinson's. A pre- and post-control study was conducted on the included patients. The results showed that intravenous transplantation of hUC-MSCs is safe and effective for Parkinson's patients, and can improve the motor function and sleep quality of Parkinson's patients.

Compared with before transplantation, it is effective 1 month after transplantation and 3 months after transplantation. It is basically stable during 1 month to 3 months, and the curative effect can be maintained until the third month. Gender and the course of the disease have an impact on the curative effect. The curative effect of women is more obvious in autonomic symptoms, cognitive function, and ability of daily living. The curative effect of RBD symptoms and RLS symptoms is more obvious in the group of disease course ≥ 5 years.

filgw.cn/m/article/Knowledg...

[Bolt_Upright]

So one trial the effects started declining at 5 years (but still above baseline) and the other the effects lasted 3 month. Thanks. I wonder how much they improved?

[Farooqji in reply to Bolt_Upright]

The one that started fading was given intravenously (not injected into the brain). It means that it can be easily repeated quarterly

[Canddy in reply to Farooqji]

I believe someone on this forum is participating in a mesenchymal stem cell study - administered via peripheral IV at the University of Texas in Houston. I tried to get into the trial but did not qualify.

[Canddy in reply to Canddy]

Here is the thread:

healthunlocked.com/cure-par...